Strata Skin Sciences ( (SSKN) ) has released its Q1 earnings. Here is a breakdown of the information Strata Skin Sciences presented to its investors.
Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
STRATA Skin Sciences, Inc. is a medical technology company focused on developing and marketing innovative dermatologic treatment products, including the XTRAC excimer laser and TheraClearX Acne Therapy System, primarily operating in the healthcare sector.
In its first-quarter 2025 financial report, STRATA Skin Sciences announced a slight increase in revenue to $6.8 million, alongside significant improvements in gross margin and a reduction in operating expenses, reflecting the company’s strategic focus on cost control and operational efficiency.
Key financial highlights from the quarter include a 1% increase in total revenue, with equipment revenue rising by 1.4% and global recurring revenue up by 1%. The company’s gross margin improved notably to 53.5%, up from 45.6% in the previous year. Operating expenses decreased by 5%, contributing to a reduced net loss of $2.4 million compared to $3.4 million in the prior year. Additionally, STRATA’s international market showed robust growth, contributing significantly to the company’s revenue.
STRATA’s direct-to-consumer strategy continues to gain traction, with a notable increase in unique psoriasis and acne patients, indicating growing demand and effective marketing efforts. The company also reported improved adjusted EBITDA, reflecting better financial management and strategic execution.
Looking ahead, STRATA Skin Sciences remains optimistic about its growth prospects, particularly in international markets, as it continues to navigate global tariff uncertainties and focuses on stabilizing and expanding its U.S. business operations.